Table 2. Analysis of factors prognostic for overall survival (N = 396).
| Clinical factors | Range | mOS (m) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | Pb | |||
| Age | ≥ 60 | 7.2 | 1.052 | 0.862–1.284 | 0.616 | |||
| <60 | 7.4 | 1 | ||||||
| Gender | Female | 7.9 | 0.883 | 0.718–1.086 | 0.240 | |||
| Male | 6.8 | 1 | ||||||
| ECOG PS | ≥ 2 | 5.6 | 1.665 | 1.300–2.133 | <0.001 | 1.406 | 1.082–1.826 | 0.011 |
| 0–1 | 7.8 | 1 | 1 | |||||
| CA19-9 | Elevated | 7.1 | 1.552 | 1.251–1.925 | <0.001 | 1.493 | 1.191–1.872 | 0.001 |
| Normal | 9.1 | 1 | 1 | |||||
| Albumin | Decreased | 6.1 | 1.380 | 1.098–1.735 | 0.006 | |||
| Normal | 7.8 | 1 | ||||||
| ALP | Elevated | 5.8 | 1.373 | 1.119–1.685 | 0.002 | |||
| Normal | 7.9 | 1 | ||||||
| Bilirubin | Elevated | 6.2 | 1.126 | 0.836–1.516 | 0.435 | |||
| Normal | 7.2 | 1 | ||||||
| NLR | <0.001 | <0.001 | ||||||
| <2.5 | 9.0 | 1 | Reference | 1 | Referenc | |||
| 2.5–4.4 | 7.2 | 1.529 | 1.214–1.925 | <0.001 | 1.659 | 1.306–2.108 | <0.001 | |
| ≥4.5 | 3.9 | 2.942 | 2.237–3.869 | <0.001 | 2.926 | 2.181–3.927 | <0.001 | |
| ΔNLRa | ≥ 0 | 6.1 | 1.247 | 1.001–1.553 | 0.049 | 1.510 | 1.204–1.895 | <0.001 |
| < 0 | 8.0 | 1 | 1 | |||||
| Lymphocyte | < 2000 | 7.1 | 1.410 | 1.119–1.777 | 0.004 | |||
| ≥ 2000 | 8.6 | 1 | ||||||
ALP, alkaline phosphatase; CA19-9, carbohydrate antigen 19–9; CI, confidential; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; mOS, median overall survival; NLR, neutrophil to lymphocyte ratio.
a (NLR after one cycle of chemotherapy)—(initial NLR).
bP values were calculated using the Multivariate Cox hazard model adjusted with age, gender, ECOG PS, CA19-9, albumin, ALP, bilirubin, NLR, ΔNLR and lymphocyte by forward stepwise selection.